# The NICE-PAD II Trial

Study · id `cardio:ct-nct07782671` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07782671](<https://clinicaltrials.gov/study/NCT07782671>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07782671

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 250 participants.

## Technical summary

Registry record NCT07782671. Randomized; quadruple masking; primary purpose treatment. Start 2027-02 (anticipated); primary completion 2030-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 250 participants (planned count; ClinicalTrials.gov record NCT07782671, source copy `cardio:ctgov-nct07782671-2026-11-16`, retrieved 2026-11-18)
- Planned start: 2027-02 (anticipated) (ClinicalTrials.gov record NCT07782671, source copy `cardio:ctgov-nct07782671-2026-11-16`, retrieved 2026-11-18)
- Primary completion: 2030-12 (anticipated) (ClinicalTrials.gov record NCT07782671, source copy `cardio:ctgov-nct07782671-2026-11-16`, retrieved 2026-11-18)
- Completion: 2031-07 (anticipated) (ClinicalTrials.gov record NCT07782671, source copy `cardio:ctgov-nct07782671-2026-11-16`, retrieved 2026-11-18)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07782671-2026-11-16`, retrieved 2026-11-18)

## The registry's words

- Brief title: The NICE-PAD II Trial
- Acronym: NICE
- Condition: Peripheral Artery Disease (PAD)
- Intervention (Drug): Nicotinamide Riboside (NR)
- Intervention (Drug): Placebo
- Lead sponsor: Northwestern University
- Lead sponsor class: OTHER
- Collaborator: National Institute on Aging (NIA)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: Northwestern University (`cardio:org-northwestern-university`)
- Registry lists this organization as a collaborator: National Institute on Aging (`cardio:nia`)

## Provenance

Content hash: 43604581d9354a08644447bc203d8e6d5dc9258b3aadf4c789e06cbc53b6bb60
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
